Imaging genetics of schizophrenia by Meyer-Lindenberg, Andreas
t is a daunting task to try to understand how
genetic and environmental risk factors are translated into
clinical symptoms, course of illness, and response to ther-
apy of the complex disease, schizophrenia. Neuroimaging
research has transformed the way we conceptualize schiz-
ophrenia. In this review, we are specifically concerned
with the contribution of neuroimaging to understanding
genetic risk. Since schizophrenia is a highly heritable dis-
order,
1 understanding how genes act to confer risk for
this devastating disease is an obvious strategy in biolog-
ical psychiatry. Clearly, genes can act on several levels,
from the gene product itself through cellular, systems-
level, and behavioral levels of description, all the way to
complex phenotypes such as therapeutic response or
impaired social interactions. The impact of genes is not
necessarily the same on each of these levels. A proposal
that has found a sizeable following in psychiatry is to
move away from disease entities such as schizophrenia to
more biologically defined levels, such as cellular, systems-
level, or neurocognitive measures, in the hope that the
effects of genes would be more prominent on these lev-
els, and that the work of psychiatric research, including
the finding of new genetic variants conferring risk for the
disorder, would be easier. This is the so-called “endophe-
notype” or intermediate phenotype concept.
2,3 While
there is evidence that this concept does not hold in gen-
eral (in the sense that there are phenotypes, for example
in the domain of cognition, that do not show higher
genetic penetrance, at least for some genes that have
been studied), the intermediate phenotype approach has
had remarkable success when neuroimaging is used as
the method of quantifying brain structure and function.
Two meta-analyses now provide convergent support for
the assertion that the penetrance of genetic variations is
high in neuroimaging.
4,5 From these studies, estimates of
449
Translational research
I
Copyright © 2010 LLS SAS.  All rights reserved www.dialogues-cns.org
Imaging genetics of schizophrenia
Andreas Meyer-Lindenberg, MD, PhD, MSc   
Keywords: schizophrenia; imaging genetics; polymorphism; COMT; ZNF804A;
dopamine; prefrontal cortex; neuroimaging
Author affiliations: Central Institute of Mental Health, Mannheim, Germany 
Address for correspondence: Andreas Meyer-Lindenberg, Central Institute of
Mental Health, J5, 68159 Mannheim, Germany  
(e-mail: a.meyer-lindenberg@zi-mannheim.de) 
Recent years have seen an explosive growth of interest
in the application of imaging genetics to understand
neurogenetic mechanisms of schizophrenia. Imaging
genetics applies structural and functional neuroimaging
to study subjects carrying genetic risk variants that relate
to a psychiatric disorder. We review selected aspects of
this literature, starting with a widely studied candidate
gene—the catechol-0-methyltransferase gene (COMT)—
discussing other candidate genes in the dopaminergic
system, and then discussing variants with genome-wide
support. In future perspectives, approaches to charac-
terize epistatic effects, the identification of new risk
genes through forward-genetic approaches using imag-
ing phenotypes, and the study of rare structural variants
are considered. 
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PAGES_11_AG_1039_BA.qxd:DCNS#45  3/12/10  12:15  Page 449effect sizes of 0.7 to 1.0 can be derived, corresponding to
sample sizes to detect genetic effects at 80% power of
around 80 participants, which is much less than would be
necessary with clinical data.
In this review, we will first discuss a paradigmatic exam-
ple of a candidate genetic variant with clear impact on
neural function related to dopamine: COMT rs4680
val/met. This is supplemented by a brief discussion of
other dopaminergic risk variants related to schizophre-
nia. We then move on to the emerging field for variants
with genome-wide association support. In conclusion, we
discuss areas of merit for further study in imaging genet-
ics of schizophrenia, both from the genetics and neural
systems-level perspective: epistasis and structural varia-
tions in the human genome.
COMT
Starting with the classic 2001 study by Egan and cowork-
ers,
6 the catechol-0-methyltransferase (COMT) gene,
COMT, has been by far the most-studied gene in the schiz-
ophrenia imaging genetics literature. COMT degrades cat-
echolamines, including dopamine (DA).
7,8 The COMT
gene consists of two promoters and six exons which
encode both the membrane-bound (MB-COMT) and sol-
uble (S-COMT) forms of COMT and is located on chro-
mosome 22q11.22-23. This region is implicated in schizo-
phrenia by linkage studies,
9 as well as in 22q11.2 deletion
syndrome, which is associated with strongly increased risk
for psychosis.
10 Of the two confirmed isoforms, MB-
COMT is predominantly expressed in the central nervous
system at neuronal dendritic processes throughout the cor-
tex, cerebellum, amygdala, putamen, thalamus, spinal cord,
and hippocampus.
11,12 Postmortem studies have shown that
COMT is particularly concentrated in the extrasynaptic
spaces of the prefrontal cortex and hippocampus.
13 Since
prefrontal dopamine transporters are scarce, COMT is
thought to play a key role in clearing dopamine in the pre-
frontal cortex.
14An evolutionarily recent functional single
nucleotide polymorphism (SNP) in COMT results in the
amino acid substitution of valine (val) with methionine
(met) at codon 158 of MB-COMT (rs4680, GenBand
accession no. Z26491, Savitz et al 2005). This substitution
leads to a significant (38%) decrease in enzymatic activity
in the brain and lymphocytes
15 of the polypeptide con-
taining the met allele compared with the val allele.
Consequently, met carriers have a higher level of pre-
frontal extracellular dopamine.
16,17
A large body of work has demonstrated an impact of
this genetic variant on cognitive and affective process-
ing. The literature on the functional aspects of the com-
mon rs4680 val/met polymorphism in COMT has been
recently reviewed.
5 In a meta-analysis of all available
functional neuroimaging studies of rs4680 up to the end
of 2008 (which are consequently not covered again in
the present review), a significant association between the
COMT genotype and prefrontal activation was found.
The effect size was large (d=0.73) without evidence for
publication bias. In the next step, studies were subdi-
vided into studies relating to executive cognition para-
digms and those that were related to emotional pro-
cessing. Strong and opposing effects were found for
executive cognition paradigms (in which more efficient
activation was found for homozygous and heterozygous
met allele carriers) and emotional paradigms (in which
the opposite was seen, more efficient activation for val
homozygotes). Effect sizes were now even larger (d=0.92
for cognitive studies and d=-1.0 for emotional para-
digms). The studies thus provided evidence for a neural
substrate for the pleiotropic behavioral effects of COMT
genetic variation, the so-called “warrior/worrier” hypoth-
esis which posits evolutionary significance for a tradeoff
between emotional processing and cognitive stability
during executive function. 
Further support for a phasic/tonic dopamine distinction
in understanding the effects of COMT genetic variation
comes from a recent study in which sustained and tran-
sient brain activity during working memory use were dis-
sociated using a mixed blocked/event-related design.
18
Albeit in a small sample (22 participants), the authors
showed that met carriers displayed a greater transient
medial temporal lobe response in the updating phase of
working memory, whereas val carriers showed a less effi-
cient sustained prefrontal cortex (PFC) activation in the
maintenance phase. Similar conclusions were reached in
a saccade task, with met carriers again more efficient
during maintenance, and val carriers during phasic task
components.
19 Importantly, rs4680 also predicted pre-
frontal activation changes under antipsychotic therapy
with olanzapine in conjunction with parallel improve-
ments in working memory performance and negative
symptoms in met-allele carriers.
20 Similarly, smokers
were more sensitive to an abstinence challenge to work-
ing memory activation in dorsolateral PFC (DLPFC)
when they were val homozygotes.
21 COMT was also
associated with an activation parameter during a fluid
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problems in novel situations) in LPFC, pre-supplemen-
tary motor area/anterior cingulate cortex, and intrapari-
etal sulcus in a small sample.
22
Compared with the functional findings, investigation of
the effects of genetic variation in COMT on brain struc-
ture has been less consistent. Multiple lines of evidence
show that extracellular dopamine is a modulator of neu-
ronal growth and survival (see ref 23 for discussion). Two
studies reported no associations between genotype and
brain volume in healthy controls,
24,25 and two reported
genotype effects in patients with schizophrenia
26 or sub-
jects at risk for psychosis
27 but in discrepant locations,
while Ho and coworkers found no differences in a group
of patients. A possible reason for these discrepancies was
identified in a recent study
23 which found a regionally
specific impact of rs4680 that differed in directionality
in PFC and hippocampus, as well as significant interac-
tions of this risk SNP with another putatively functional
SNP in the promoter region (reviewed below). A further
source of variance was suggested by a study showing
that IQ modulates the effects of rs4680 in prefrontal and
hippocampal white matter fractional anisotropy,
28 mir-
roring the lateral PFC (LPFC) results observed in func-
tion.
22
Other dopaminergic risk genes
Three risk single nucleotide polymorphisms (SNPs) in the
gene for the dopamine D2 receptor, DRD2, showed
opposite effects in patients and controls during a working
memory task: enhanced engagement of prefronto-striatal
pathways in controls and reduced activity in patients,
29
presumably because patients and controls are positioned
on opposite sides of the inverted-u-shaped curve govern-
ing the relationship of dopaminergic simulation and pre-
frontal activity. On the postsynaptic side, Regulator of G-
protein signaling 4 (RGS4) modulates dopamine signal
transduction by affecting G alpha-GTP binding. Allelic
variation in RGS4 by itself modulated frontoparietal and
frontotemporal activation during working memory and
was associated with frontal gray and white matter struc-
tural volume reductions.
30 Further into the postsynapse,
the pivotal integrator of information in dopaminoceptive
neurons for the so-called canonical signal transduction
pathway is dopamine- and cAMP-regulated phospho-
protein of molecular weight 32 kDa (DARPP-32),
encoded by the gene PPP1R1B. A frequent PPP1R1B
haplotype related to risk for schizophrenia predicted
reduced striatal volume and activation (in good agree-
ment with the expression profile of DARPP-32) and
increased structural and functional connectivity of stria-
tum with lateral prefrontal cortex in a large sample of
genotyped healthy controls.
31 Interestingly, genetic vari-
ation in AKT1, encoding another key signal transduction
pivot, but now for the non-canonical, beta-arrestin medi-
ated dopaminergic pathway, similarly predicted reduced
frontostriatal volume as well as inefficient prefrontal acti-
vation during working memory.
32Taken together, these
two studies provide strong support for the prefronto-
neostriatal system as a core circuit for dopaminergic vari-
ation related to schizophrenia risk. Investigating a panel
of dopamine-related genes during a reward task,
33 poly-
morphisms in DRD2 (141C deletion), DAT1 (9-repeat)
and DRD4 (7-repeat), were related to ventral striatal
activity, while COMT rs4680 was not, in agreement with
its predominant role in prefrontal cortex activity. 
Genome-wide significant variants
Despite their clear and often convergent impact on
imaging phenotypes, the usefulness of candidate genes
for understanding schizophrenia is debated because
these a-priori hypothesized variants often show an
inconsistent effect on the categorical disease phenotype
itself. Genome-wide association studies (GWAS) offer
an alternative, hypothesis-free way to identify genetic
variants associated with the disease. While it is in our
view unlikely that GWAS will provide all answers about
common genetic variants impacting on schizophrenia,
any variant that does survive the extreme amount of sta-
tistical thresholding that this method requires certainly
merits study using intermediate imaging phenotypes.
Several such variants have been forthcoming in schizo-
phrenia, in particular ZNF804A, Neurogranin, TCF4,
and genes located in the major histocompatibility com-
plex.
34-36 Of those variants, the one with the strongest sup-
port is ZNF804A, encoding a zinc-finger protein of
unknown, but possibly regulatory function. Interestingly,
like the COMT candidate gene variant discussed here,
ZNF804A appeared to be promiscuous on the level of
psychiatric diagnoses, also being associated with bipolar
disorder. In functional neuroimaging with an n-back
working memory probe,
37 healthy carriers of ZNF804A
rs1344706 risk genotypes exhibit no changes in regional
activity. However, they did exhibit pronounced gene
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which was measured by correlating the time series of
activity across regions. Functional connectivity was
decreased from DLPFC across hemispheres and
increased with hippocampus. Both of these connectivity
profiles mirrored findings in patients and carriers of can-
didate risk variants, providing translational genetic sup-
port for the contention first put forward by Wernicke
more than 100 years ago that abnormal functional cou-
pling between brain areas is an important mechanism of
schizophrenia. Interestingly, cognitive performance of
patients with the ZNF804A risk genotype has been
linked to working and episodic memory specifically,
highlighting to core functions to which DLPFC and hip-
pocampus contribute.
38
New frontiers in imaging genetics 
of schizophrenia
Work discussed so far has concerned the effects of sin-
gle genetic variants on brain phenotypes. While imaging
genetics has proven itself to be a sensitive and specific
assay of such effects, the present data do not allow the
prediction of phenotypes using these genetic findings,
largely due to the fact that the amount of variance attrib-
utable to each common genetic variant in isolation is too
small. The application of imaging genetics is therefore
evolving to address key questions posed by the genetic
complexity of schizophrenia. Here, we will discuss three
of these research frontiers: epistasis, the study of rare
structural variants in the genome, and discovery science
using imaging genetics.
Epistasis
The genetics of schizophrenia is complex; while heri-
tability is high, recent results from GWAS strongly sug-
gest that no frequent variant exists that by itself
increases disease risk by more than 30%.
34-36 In fact, sim-
ulation studies indicate that thousands of risk alleles may
be related to heritability in this genetically complex dis-
order.
34 This implies that interactions between genes,
“epistasis,” may play an important role in the disorder,
and may also contribute to the interactions with the
environment. A convenient starting point for investigat-
ing epistasis is again provided by COMT, since this gene
harbors several functional or likely functional polymor-
phisms. A cis functional variant (rs2097603) linked
upstream in the P2 promoter, driving transcription of the
predominant form of COMT in the brain (MB-COMT),
affects COMT activity in lymphocytes and postmortem
brain tissue.
15 Another variant in the 3' untranslated
region (rs165599), highly associated with schizophrenia
in a large sample of Israelis of Ashkenazi descent,
39 was
found to differentially affect expression of rs4680 alleles
in human brain tissue.
40 A further variant impacting on
COMT transcription, through an alteration of mRNA
structure, has been identified. Using probabilistic hap-
lotype mapping in a large sample of healthy controls
studied during working memory,
41 evidence for func-
tional interactions of rs4680 with rs2097603 and rs165599
was indeed found, with a neural response that con-
formed to the inverted-u model. Similarly in brain struc-
ture, interactions between rs4680 and rs2097603 in hip-
pocampal gray matter volume were found that were
again consistent with a nonlinear (inverted u) effect.
23
For function, Bertolino and coworkers,
42 studying work-
ing memory in healthy subjects, showed that the COMT
met158 allele and the DAT 3' variable number of tan-
dem repeat 10-repeat allele were independently associ-
ated in healthy humans with more efficient BOLD
response in the prefrontal cortex, and that these effects
were additive (subjects homozygous for the COMT met
allele and the DAT 10-repeat allele had the most effi-
cient response, whereas the combination of the COMT
val and the DAT 9-repeat alleles the least). Very simi-
lar results were obtained by Caldu and coworkers.
43
Conversely, during response inhibition, greater activa-
tion (reduced efficiency) was observed in carriers of the
DAT 9-allele or the COMT met-allele as compared with
carriers of the DAT 10/10 genotype and COMT val/val
homozygotes,
44 a finding that could reflect differing pro-
cessing demands during inhibition, which is a more pha-
sic process, as compared with working memory mainte-
nance, which requires tonic activity.
17A true interaction
between these variants was also found in a multimodal
imaging study using a reward paradigm,
45 measuring
midbrain dopamine synthesis with F-DOPA positron
emission tomography (PET) and activation during
reward anticipation in the ventral striatum, lateral pre-
frontal and orbitofrontal cortices as well as in the mid-
brain at the time of reward delivery, with carriers of the
DAT1 9-repeat allele and COMT met/met allele exhibit-
ing the least efficiency, similar to the finding during inhi-
bition and presumably reflecting functional changes con-
sequent to higher synaptic dopamine availability in the
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working memory and episodic memory (retrieval),
Bertolino and coworkers found nonlinear, true epistatic
interactions between the same genetic variants in hip-
pocampus, conforming to an inverted-u model, suggest-
ing that epistatic phenomena vary by region (and possi-
bly cognitive condition).
46The modulator of postsynaptic
dopamine signaling, RGS4, showed an interaction with
COMT rs4680 genotype in DLPFC and midbrain during
working memory: val/val subjects demonstrated a sig-
nificant allele-dosage effect (increasing linearly with the
number of minor alleles) of RGS4 on prefrontal BOLD,
while the effect of RGS4 was attenuated in met-carrying
subjects.
47 A risk variant in another postsynaptic signal-
ing molecule gene, AKT1, similarly showed interactions
with COMT rs4680 genotype during working memory,
32
with risk carriers for both genes showing especially inef-
ficient lateral prefrontal activation.
While the papers reviewed above are limited to interac-
tions between a maximum of four SNPs, the complexity
of common genetic variation related to schizophrenia,
which is likely to include effects of thousands of variants,
will require a methodological effort to characterize
interactions between larger sets of genes as they impact
on imaging data. Calhoun and coworkers employed par-
allel independent component analysis, applied to audi-
tory oddball task fMRI data, and extracted a set of 10
SNPs that were significantly related to imaging data and
differed between a sample of patients and controls.
48
While selection of SNPs and small sample size preclude
conclusions about the specific genes they highlighted,
their study provides proof of concept of the applicabil-
ity of multivariate methods in imaging genetics.
Copy number variants
An important insight that has emerged from the last
waves of genome-wide studies of schizophrenia concerns
structural variations of the genome, where larger seg-
ments (up to several megabases) of genetic material are
either duplicated (microduplications) or missing
(microdeletions).
49,50 Convergent evidence now shows
that such copy number variants (CNVs) are more com-
mon in schizophrenia than in the general population. In
contrast to frequent genetic variants such as SNPs, the
risk associated with some CNVs is much higher, and can
correspond to a tenfold increase in disease risk. There is
evidence that the presence of these variants is deleteri-
ous since they are under negative selection.
51 Several
specific regions now have strong evidence for conferring
risk for schizophrenia, mapping on chromosome regions
at 22q11, 15q13.3, 1q21.1, 15q11.2, 17p12, 2p16.3, 16p13.1,
and 16p11.2. One of these, 22q11, has been known for a
longer time since this microdeletion causes a clinical syn-
drome (velocardiofacial, DiGeorge, or 22q11 deletion
syndrome) that is recognizable by a pattern of somatic
symptoms, such as heart defects or cleft palate, in addi-
tion to the increased risk for psychosis.
52 An important
research frontier will be to understand, using imaging
genetics, how these microdeletions impact on brain
structure and function. This work is farthest in 22q11DS,
which has been known for the longest time. Here, con-
vergent evidence implicates reductions in hippocampus
and cerebellum, abnormal white matter connectivity,
especially in the posterior corpus callosum, and reduced
prefrontal activation (possibly compensated by parietal
activation) during working memory tasks.
53 For the other
microdeletions, only recently identified, evidence is
emerging that they also cause complex neurodevelop-
mental syndromes whose psychiatric manifestations
include, not only psychosis, but also intellectual impair-
ment, and features of autism and attention deficit–
hyperactivity disorder.
53 While these are therefore not
monocausally related to schizophrenia, they are one of
the best genetic clues yet for a genetical high-risk state
that deserves intensive further study. This applies both
to chartacterizing brain phenotypes in subjects carrying
or not carrying the disorder, and to trying to further dis-
sect why these, and not any of the many other
microdeletions present in the human population,
increase risk for psychosis. For the former approach, the
main problem is that due to the relative rarity of these
variants even in clinical populations, large numbers will
have to be screened and characterized. Nevertheless, this
work is ongoing and promises insights not only in study-
ing the phenotypes of each of these variants by itself, but
also in examining whether there are overlaps in struc-
tural or neurofunctional impairments across these
microdeletions that would identify core systems related
to a high-risk state. For the latter attempt of trying to
understand why these specific microdeletions are high-
risk, complex cis- and trans-acting genetic effects (ie,
those that concern the genes affected by the microdele-
tion itself, or outside of it) will have to be considered.
However, a simple hypothesis that can be tested is
whether there could be, by chance, several common risk
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that are jointly affected by a microdeletion, causing a
superadditive effect. Some preliminary evidence for this
idea comes from 22q11DS, which includes the much-
studied risk gene COMT, discussed above, but also sev-
eral other genes where schizophrenia risk variants have
been studied. One of these, PRODH, encoding proline
oxidase (POX), has been associated with schizophrenia
through linkage and association. A recent study showed
that functional polymorphisms had opposite effects on
schizophrenia risk depending on whether they increased
or decreased POX activity.
54 In multimodal genetic imag-
ing, both functional (working memory and emotional
recognition) and structural (VBM) datasets showed dis-
sociable genetic effects: risk haplotype carriers had
decreased striatal volume and increased striatal-frontal
functional connectivity, while the protective haplotype
was associated with decreased striatal-frontal functional
connectivity, mirroring findings in patients and suggest-
ing that functional genetic variation in POX impacts on
neostriatal-frontal circuits mediating risk and protection
for schizophrenia. Since, as reviewed above, the bio-
chemically unrelated COMT gene on overlapping cir-
cuitry in human brain, this suggests a neural mechanism
whereby deletion of both genes in 22q11 syndrome
could have a superadditive impact on schizophrenia risk.
Further work, which needs to take epistatic and trans-
acting effects into account, is necessary to extend these
findings. 
Forward genetics—discovery science
Finally, an important future perspective of imaging
genetics is to use it to find new variants associated with
brain phenotypes, as a forward genetics method. Since
the penetrance of common genetic variants is higher on
the level of neuroimaging, this approach, which requires
a combination of neuroimaging with genome-wide asso-
ciation data, is feasible with a considerably smaller num-
ber of subjects than when using clinical phenotypes. First
examples of this approach have appeared
55; with regard
to structural variants, some are now close to genome-
wide significance.
56 It is likely that samples from several
groups will have to be combined to bring this approach
to full fruition; in this sense, imaging genetics will follow
the trend of psychiatric genetic in general. This research
strategy has considerable potential to identify new mol-
ecular targets affecting given brain systems; if these sys-
tems (and ideally also the genetic variants) can be linked
to schizophrenia, this would provide a much-needed
impetus for drug discovery in this still insufficiently
treatable psychiatric disorder.
Conclusion
In summary, we have provided an overview of the results
obtained from studying both candidate and genome-
wide supported common genetic variants using neu-
roimaging. Those results converge on effects in lateral
prefrontal cortex and subcortical structures with which
it is densely interconnected, in particular striatum and
hippocampus, highlighting a core neural system for
genetic risk for schizophrenia. Future work will increas-
ingly consider epistatic effects of multiple common vari-
ants, characterize rare high-risk structural variants, and
use imaging data to discover new genetic contributions
to neural structure and function that can lead to new
treatments.  ❏
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Imagenología de la expresión genética 
en la esquizofrenia
En los últimos años ha habido un explosivo interés
en la aplicación de la imagenología vinculada con
la genética para comprender los mecanismos neu-
rogenéticos de la esquizofrenia. La imagenología
de la genética aplica neuroimágenes estructurales
y funcionales al estudio de sujetos portadores de
variantes de riesgo genético relacionadas con un
trastorno psiquiátrico. Se revisan aspectos seleccio-
nados de esta literatura, comenzando con un gen
candidato ampliamente estudiado –el gen de la
catecol-O-metiltransferasa (COMT)- luego se discu-
ten otros genes candidatos en el sistema dopami-
nérgico y finalmente se analizan variantes susten-
tadas en el genoma completo. A futuro hay que
considerar las aproximaciones que permitan carac-
terizar los efectos epistáticos, la identificación de
nuevos genes de riesgo mediante propuestas de
genética avanzada que emplea imagenología de
fenotipos y el estudio de variantes estructurales
raras. 
Imagerie génétique de la schizophrénie
L’intérêt pour les applications de l’imagerie  géné-
tique a explosé ces dernières années dans le but de
comprendre les mécanismes neurogénétiques de la
schizophrénie. L’imagerie  génétique utilise la
neuro-imagerie fonctionnelle et structurelle pour
étudier les sujets porteurs de variants de risque
génétique lié à un trouble psychiatrique. Nous
analysons dans cet article une sélection de la litté-
rature, en commençant par celle concernant un
gène candidat très étudié, la catéchol-0-
méthyltransférase (COMT), puis en discutant l'im-
plication d’autres gènes candidats du système dopa-
minergique et enfin de variants à l’échelle du
génome entier. Dans les perspectives futures, nous
analyserons  la manière de caractériser les effets
épistatiques, l’identification de nouveaux gènes de
risque à l’aide d’approches génétiques modernes
utilisant l’imagerie des phénotypes et l’étude de
variants structuraux rares.
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